PuSH - Publikationsserver des Helmholtz Zentrums München: Heterozygous variants in <em>CTR9</em>, which encodes a major component of the PAF1 complex, are associated with a neurodevelopmental disorder.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Meuwissen, M.* ; Verstraeten, A.* ; Ranza, E.* ; Iwaszkiewicz, J.* ; Bastiaansen, M.* ; Mateiu, L.* ; Nemegeer, M.* ; Meester, J.A.N.* ; Afenjar, A.* ; Amaral, M.* ; Ballhausen, D.* ; Barnett, S.* ; Barth, M.* ; Asselbergh, B.* ; Spaas, K.* ; Heeman, B.* ; Bassetti, J.* ; Blackburn, P.* ; Schaer, M.* ; Blanc, X.* ; Zoete, V.* ; Casas, K.* ; Courtin, T.* ; Doummar, D.* ; Guerry, F.* ; Keren, B.* ; Pappas, J.* ; Rabin, R.* ; Begtrup, A.* ; Shinawi, M.* ; Vulto-van Silfhout, A.T.* ; Kleefstra, T.* ; Wagner, M. ; Ziegler, A.* ; Schaefer, E.* ; Gérard, B.* ; De Bie, C.I.* ; Holwerda, S.J.B.* ; Abbot, M.A.* ; Antonarakis, S.E.* ; Loeys, B.*

Heterozygous variants in CTR9, which encodes a major component of the PAF1 complex, are associated with a neurodevelopmental disorder.

Genet. Med. 24, 1583-1591 (2022)

Verlagsversion

DOI

PMC

	Closed

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

Purpose: CTR9 is a subunit of the PAF1 complex (PAF1C) that plays a crucial role in transcription regulation by binding CTR9 to RNA polymerase II. It is involved in transcription-coupled histone modification through promoting H3K4 and H3K36 methylation. We describe the clinical and molecular studies in 13 probands, harboring likely pathogenic CTR9 missense variants, collected through GeneMatcher. Methods: Exome sequencing was performed in all individuals. CTR9 variants were assessed through 3-dimensional modeling of the activated human transcription complex Pol II-DSIF-PAF-SPT6 and the PAF1/CTR9 complex. H3K4/H3K36 methylation analysis, mitophagy assessment based on tetramethylrhodamine ethyl ester perchlorate immunofluorescence, and RNA-sequencing in skin fibroblasts from 4 patients was performed. Results: Common clinical findings were variable degrees of intellectual disability, hypotonia, joint hyperlaxity, speech delay, coordination problems, tremor, and autism spectrum disorder. Mild dysmorphism and cardiac anomalies were less frequent. For 11 CTR9 variants, de novo occurrence was shown. Three-dimensional modeling predicted a likely disruptive effect of the variants on local CTR9 structure and protein interaction. Additional studies in fibroblasts did not unveil the downstream functional consequences of the identified variants. Conclusion: We describe a neurodevelopmental disorder caused by (mainly) de novo variants in CTR9, likely affecting PAF1C function.

Impact Factor

Scopus SNIP

Altmetric

8.864

2.730